Octreoscan (Indium In-111 Pentetreotide)

Indium In-111 pentetreotide, the active ingredient in Octreoscan, is a somatostatin analog presented as a radiopharmaceutical for intravenous use. It is employed in diagnostic imaging to locate neuroendocrine tumors and assess disease extent in adult patients. GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

Octreoscan is a radiolabeled somatostatin analogue that targets somatostatin receptor‑positive neuroendocrine tumors.

- Gastroenteropancreatic neuroendocrine tumors: helps detect the presence and anatomical distribution of disease. - Carcinoid syndrome tumors: assists in staging and therapeutic planning by visualising receptor‑positive lesions. - Medullary thyroid carcinoma: aids in identifying metastatic sites for surgical or systemic treatment decisions. - Small‑cell lung cancer (rare indication for imaging research).

Adverse reactions are generally related to the radiopharmaceutical and the injection process.

Common Side Effects: - Nausea: mild to moderate, often transient. - Flushing: brief erythema and warmth, usually self‑limiting. - Headache: mild discomfort occurring shortly after administration. - Injection site pain: localized tenderness at the venous access point. - Transient hypotension: brief drop in blood pressure during or after injection.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of airway swelling, hives, or circulatory collapse. - Significant radiation‑induced organ toxicity: especially to kidneys or bone marrow with high cumulative exposure. - Persistent hypotension requiring medical intervention. - Acute hemolysis or hematuria. - Development of secondary malignancies (theoretical risk with high cumulative doses).

Octreoscan should be used only under the supervision of physicians experienced in nuclear medicine imaging.

- Pregnancy testing: perform before administration because radiation may affect fetal development. - Breastfeeding: discontinue nursing for an appropriate period after dosing due to possible radiotracer excretion. - Renal function: assess baseline kidney function; adjust or avoid in severe impairment. - Concomitant radiopharmaceuticals: avoid simultaneous use to prevent overlapping radiation exposure. - Allergic history: verify no prior severe reaction to somatostatin analogues or indium‑based agents. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreoscan may interact with other agents that influence radiation exposure or somatostatin receptor activity.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: may lead to additive radiation dose and increased toxicity. - High‑dose somatostatin analog therapy (e.g., octreotide infusion): can compete for receptor binding and reduce imaging quality.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): may exacerbate renal radiation exposure. - Diuretics: can alter renal clearance of the tracer, affecting dosimetry. - Antihistamines or steroids: may mask mild allergic reactions, delaying recognition. - Chemotherapy agents: consider timing to avoid overlapping toxicity. - Contrast agents used in CT: schedule appropriately to prevent image artefacts.